Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 15;214(4):607-11.
doi: 10.1093/infdis/jiw204. Epub 2016 Jun 20.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals

Philip M Grant  1 , Douglas Kitch  2 , Grace A McComsey  3 , Ann C Collier  4 , Susan L Koletar  5 , Kristine M Erlandson  6 , Michael T Yin  7 , Benedetta Bartali  8 , Belinda Ha  9 , Kathy Melbourne  10 , Todd T Brown  11
Affiliations

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals

Philip M Grant et al. J Infect Dis. .

Abstract

We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

Keywords: HIV infections, drug therapy/virology; anti-HIV agents, administration and dosage, adverse effects; bone density.

PubMed Disclaimer

References

    1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165–74. - PubMed
    1. Grant PM, Kitch D, McComsey GA et al. . Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013; 57:1483–8. - PMC - PubMed
    1. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS 2013; 27:1949–57. - PMC - PubMed
    1. McComsey GA, Kitch D, Daar ES et al. . Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791–801. - PMC - PubMed
    1. Sax PE, Wohl D, Yin MT et al. . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606–15. - PubMed

Publication types

Substances